sponsored
PatientsVille.com Logo

PatientsVille

Hyperthyroidism Medical Research Studies

Up-to-date List of Hyperthyroidism Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hyperthyroidism Medical Research Studies

Rank Status Study
1 Unknown  Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?
Condition: Hyperthyroidism
Intervention: Procedure: treatment with 131I
Outcome Measure: To provide evidence that restoration of euthyroidism (normal TSH) improves thyrotoxic symptoms and signs and quality of life and lowers the risk of subsequent atrial fibrillation and bone loss in subjects with endogenous subclinical Hyperthyroidism
2 Unknown  Treatment of Subclinical Hyperthyroidism
Conditions: Subclinical Hyperthyroidism;   Atrial Fibrillation
Intervention:
Outcome Measure:
3 Recruiting Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism
Condition: Graves' Hyperthyroidism
Interventions: Dietary Supplement: Selenium;   Other: Placebo
Outcome Measures: Proportion of participants with the composite outcome of 'ATD treatment failure';   Proportion of participants who receives ATD treatment (at any level) during the last 12 months (± 1 month) of the intervention period;   Proportion of participants who has thyroid hyperfunction (TSH <0.1) during the last 12 months (± 1 month) of the intervention period;   Proportion of participants who has been referred to ablative therapy (radioactive iodine or thyroid surgery) at some point during the entire intervention period;   Thyroid-specific QoL during the first year after randomisation, and at the end of the intervention period (24-30 months), as measured by the global score in the ThyPRO questionnaire;   Level of TRAb at 18 months, and at the end of the intervention period (24-30 months);   Hyperthyroid symptoms (ThyPRO subscale) during first year after randomisation;   Eye symptoms (ThyPRO subscale) during first year after randomisation, and at end of the intervention period (24-30 months);   Number of participants with adverse reactions during the intervention period;   Number of participants with serious adverse events during the intervention period
4 Recruiting Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery?
Conditions: Atrial Fibrillation;   Subclinical Hyperthyroidism
Intervention:
Outcome Measures: Prevalence of subclinical Hyperthyroidism in patients undergoing atrial fibrillation ablation;   Recurrent atrial fibrillation after ablation
5 Unknown  Treatment of M.Graves With Radioactive Iodine: Follow-up Study
Condition: Hyperthyroidism
Intervention:
Outcome Measure:
6 Recruiting Thumb-ECG Ambulant Screening for Atrial Fibrillation in Hyperthyroid Patients Treated With Radioiodine
Conditions: Hyperthyroidism;   Atrial Fibrillation
Intervention:
Outcome Measures: Prevalence of asymptomatic (silent) atrial fibrillation in hyperthyroid patients;   Prevalence of asymptomatic (silent) atrial fibrillation in patients treated for Hyperthyroidism.;   Prevalence of risk factors for stroke in patients with atrial fibrillation
7 Recruiting Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Conditions: Hyperthyroidism;   Hypothyroidism
Intervention:
Outcome Measure: Thyroid extreme CT
8 Recruiting Effects of Hyperthyroidism on Amount and Activity of Brown Adipose Tissue
Condition: Hyperthyroidism
Intervention:
Outcome Measures: FDG-PET/CT-scanning;   Indirect Calorimetry
9 Unknown  Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction
Conditions: Subclinical Hypothyroidism;   Hyperthyroidism;   Thyroid Dysfunction
Intervention:
Outcome Measure:
10 Recruiting Evaluation of Patients With Thyroid Disorders
Conditions: Hyperthyroidism;   Hypothyroidism;   Pituitary Neoplasm
Intervention:
Outcome Measure:
11 Recruiting Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
Condition: Graves Disease (Basedow's Disease)
Interventions: Drug: the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;   Drug: The initiation of LT4 as soon as the first biological signs of hypothyroidism.
Outcome Measures: will assess differences in terms of quality of life at 3 months using a specific questionnaire (ThyPRO).;   compare quality of life outcomes at different study visits (using ThyPRO and SF36), fatigue (MFIS) and depression (Beck), autoimmune parameters (signs of ophthalmopathy, TSH receptor antibodies assessment), efficacy and medico-economic data.
12 Recruiting Shared Decision Making in Graves Disease - Graves Disease (GD) Choice
Conditions: Graves' Disease;   Thyroid Disease;   Hyperthyroidism
Intervention: Other: Decision Aid
Outcome Measure: Decisional Quality (Knowledge, Decisional Conflict, Satisfaction) of 100 participants
13 Recruiting Comparative Study of Different I-131 Doses in Graves' Disease
Condition: Graves' Disease
Interventions: Drug: Low dose of I-131;   Drug: Intermediate dose;   Drug: High dose
Outcome Measures: change of thyroid related hormones blood level from baseline at 1,3,6 and 12 month;   Rate of hypothyroidism status at 1, 3,6 and 12 month post RAI therapy
14 Not yet recruiting Fetal Thyroid Ultrasound And Fetal Thyroid Hormones
Conditions: Pregnancy Complicated by Hyperthyroidism;   Hypothyroidism in Pregnancy
Intervention:
Outcome Measures: Fetal thyroid size measured by ultrasonography;   Fetal fT4;   Fetal antithyroid antibodies;   Maternal fT4;   Maternal TSH;   Maternal antithyroid antibodies
15 Unknown  Thyroid Hormones Effect on Brown Adipose Tissue
Condition: Hyperthyroidism
Intervention:
Outcome Measure:
16 Not yet recruiting Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: BMS-936559;   Drug: Placebo for BMS-936559
Outcome Measures: Occurrence of a Grade 3 or greater adverse event (AE), including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment;   Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), myocarditis, pneumonitis, uveitis, immune-mediated Hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study;   Frequency of HIV-1 Gag-specific CD8 T-cells by intracellular staining for interferon (IFN)-gamma at baseline and after treatment (through Day 28);   HIV-1 RNA by single copy assay (SCA) at baseline and after treatment (through Day 28);   PK parameters from non-compartmental analysis (area under curve [AUC], Cmax, V, Tmax, CL/F, t1/2);   Exploratory pharmacodynamic parameters (Emax, EC50);   HIV-1 DNA at baseline and after treatment;   Programmed cell death 1 ligand 1 (PD-L1) receptor occupancy;   Proportion of total and HIV-1 gag-specific CD8 T-cells expressing programmed cell death 1 (PD-1), PD-L1, and other exhaustion markers;   CD107a mobilization and carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution of HIV-1 gag-specific CD8 T-cells;   Polyfunctionality of HIV-1 specific CD8 and CD4 T-cells;   CD38 and human leukocyte antigen-DR (HLA-DR) expression on CD8 T-cells;   Gene expression profiles in whole blood;   Detection of antibody to study treatment in plasma;   Occurrence of a Grade 3 or greater AE, including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment;   Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), myocarditis, pneumonitis, uveitis, immune mediated Hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study;   2-long terminal repeat (2LTR) circle DNA at baseline and after treatment;   Cell-associated HIV-1 RNA at baseline and after treatment;   RNA/DNA ratios in total CD4 cells at baseline and after treatment;   Expression of programmed cell death 1 ligand 2 (PD-L2) on dendritic cells and monocyte-derived macrophages
17 Unknown  The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy
Condition: Graves' Ophthalmopathy
Interventions: Procedure: Total Thyroidectomy;   Drug: Propylthiouracil
Outcome Measure: Improvement in the proptosis and activity of Graves' ophthalmopathy
18 Recruiting Radioactive Iodide Therapy for Pediatric Graves' Disease
Condition: Graves' Disease
Interventions: Radiation: RAI treatment;   Drug: ATD Group
Outcome Measures: Dosimetry Studies;   Cancer risk assessment
19 Unknown  TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease
Condition: Graves' Disease
Intervention:
Outcome Measure:
20 Recruiting Radiofrequency Ablation in Thyroid Nodules
Condition: Thyroid Nodules
Intervention: Procedure: Radiofrequency ablation of the thyroid nodule
Outcome Measures: Shrinkage of the thyroid nodule after radiofrequency ablation;   Disappearance of the nodules in follow up

These studies may lead to new treatments and are adding insight into Hyperthyroidism etiology and treatment.

A major focus of Hyperthyroidism research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Hyperthyroidism